Project Grant R21CA299372
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $218K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Cancer Institute, within the Department of Health and Human Services, awarded $442,146 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a first-in-class clinical trial of natural killer cell therapy engineered to target intracellular antigens in acute myeloid leukemia and high-risk myelodysplastic syndromes. The funded work develops and tests cord blood-derived, off-the-shelf NK cells...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded The Johns Hopkins University $155,479 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate an antibody-drug conjugate targeting CCRL2 for treatment of high-risk myelodysplastic syndrome and myelodysplastic syndrome-related acute myeloid leukemia, particularly in patients with TP53 mutations. The funded work includes patient-derived xenograft studies and assessment of the anti-CCRL2 ADC efficacy and safety in an...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $387,156 on August 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to advance TGF-beta-resistant CAR-NK cell therapy for acute myeloid leukemia. The work targets relapsed/refractory AML through a clinical trial using cord blood-derived CAR-NK cells engineered to express a truncated human CD27, CD28 costimulatory domain, CD3-zeta signaling domain, IL-15, and an inducible caspase-9 safety...
- The National Institutes of Health National Cancer Institute awarded The Research Foundation For The State University Of New York $724,196 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) for a Project Grant (R01CA308325) investigating HLA-independent CD8+ T cell immunotherapy against acute myeloid leukemia. The research develops a novel therapeutic strategy to overcome HLA Class I downregulation on leukemic cells, which enables tumors to evade conventional CD8+ T...
- The National Cancer Institute awarded The Johns Hopkins University $387,178 on August 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop lipid nanoparticle-based immunotherapy strategies for in-situ generation of dual T cell receptor/chimeric antigen receptor T cells targeting cancer. The award funds research to address the barrier of scalable systems for delivering genetic material to CD4+ T cells. The project leverages a high-throughput mRNA lipid...
- The National Cancer Institute (a component of the Department of Health and Human Services National Institutes of Health) awarded Northwestern University $1,431,654 on September 23, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate how leukemia stem cell persistence during tyrosine kinase inhibitor treatment in chronic myeloid leukemia is influenced by interaction with CD8+ T cells. The research will employ single-cell RNA sequencing and murine transplant models to...
- The National Cancer Institute awarded The Johns Hopkins University $644,632 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates targeting gamma-delta T-cell cancers. The award funds research to establish a mechanistic link between genomic alterations in gamma-delta T-cell leukemias and lymphomas and MYC-driven oncogenesis. The recipient will engineer mutations observed in these cancers into normal cells to quantify how genetic...
- The National Cancer Institute awarded Northwestern University $593,307 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying nucleophosmin 1 (NPM1)-driven acute myeloid leukemia leukemogenesis. The funded research examines how NPM1 cytoplasmic mutations (NPM1c), which occur in approximately 30 percent of adult de novo AML cases, cooperate with clonal hematopoiesis mutations in DNMT3A, TET2, or IDH1/2 to promote leukemic...
- The National Cancer Institute awarded the University of California Irvine $586,364 on April 7, 2026, for a Project Grant (R01CA308352) under the Cancer Biology Research program (CFDA 93.396). The research investigates Group 1 innate lymphoid cells (ILCs), particularly ILC1s, as a potential therapeutic approach to acute myeloid leukemia (AML). Prior work published by the recipient in Nature Immunology demonstrated that ILC1s from healthy donors induce the death of leukemia stem cells and block...